Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives.

Cancers (Basel) · 2022 · PMC9688939 · PMID 36428582

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

In the IMspire150 study, triple therapy showed a significantly better PFS in patients with elevated LDH as well as a numerical trend towards better outcomes in patients with a high tumor mutational burden [ 30 ].

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.